Pharmaceutical

Cardurion closes $260m in Series B to develop cardiovascular pipeline

The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.

Jul 18, 2024 - 04:00
Cardurion closes $260m in Series B to develop cardiovascular pipeline
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.
Read the original article

Tags:

Previous Article

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

Next Article

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘Worse than what we thought’: New data reveals deeper problems with the Bureau of Prisons’ Covid response

‘Worse than what we thought’: New data reveals deeper p...

May 23, 2023

STAT+: Judge tosses PhRMA lawsuit over Medicare power to negotiate drug prices

STAT+: Judge tosses PhRMA lawsuit over Medicare power t...

Feb 13, 2024

Medicare Advantage update pushes Wall Street to reset expectations

Medicare Advantage update pushes Wall Street to reset e...

Jan 22, 2024